{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:38:56Z","timestamp":1793335136799,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Blood Cancer United","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"University of Michigan Rogel Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100253","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:40:58Z","timestamp":1780591258000},"page":"100253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Menin inhibitors as a treatment for acute leukemia: from bench to the clinic"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-5482","authenticated-orcid":false,"given":"Justin","family":"Watts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-9958","authenticated-orcid":false,"given":"Ellen","family":"Madarang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Cierpicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Grembecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bneo.2026.100253_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35834","article-title":"Top advances of the year: acute myeloid leukemia","volume":"131","author":"Thakur","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100253_bib3","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2012-05-429274","article-title":"Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100253_bib4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/jm401868d","article-title":"High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction","volume":"57","author":"He","year":"2014","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bneo.2026.100253_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acs.jmedchem.5b01305","article-title":"Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemia (MLL)","volume":"59","author":"Borkin","year":"2016","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/leu.2015.144","article-title":"Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner","volume":"30","author":"He","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100253_bib8","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1021\/acs.jmedchem.8b00071","article-title":"Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction","volume":"61","author":"Borkin","year":"2018","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bneo.2026.100253_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025031201","article-title":"Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models","author":"Miao","year":"2026","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.bneo.2026.100253_bib12","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7954","key":"10.1016\/j.bneo.2026.100253_bib13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100253_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2025.08.001","article-title":"Menin inhibition for the treatment of acute leukemia","volume":"62","author":"Wenge","year":"2025","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer-associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.bneo.2026.100253_bib19","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100253_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"9321","key":"10.1016\/j.bneo.2026.100253_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"Pui","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.bneo.2026.100253_bib22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4161\/cbt.8.13.8924","article-title":"MLL fusions: pathways to leukemia","volume":"8","author":"Liu","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"10.1016\/j.bneo.2026.100253_bib24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100253_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"52","key":"10.1016\/j.bneo.2026.100253_bib26","doi-asserted-by":"crossref","first-page":"40690","DOI":"10.1074\/jbc.M110.172783","article-title":"Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias","volume":"285","author":"Grembecka","year":"2010","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100253_bib29","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.leu.2404808","article-title":"Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias","volume":"21","author":"Mullighan","year":"2007","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bneo.2026.100253_bib30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"6477","key":"10.1016\/j.bneo.2026.100253_bib31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12185-018-02578-7","article-title":"New insights into the biology of acute myeloid leukemia with mutated NPM1","volume":"110","author":"Brunetti","year":"2019","journal-title":"Int J Hematol"},{"issue":"25","key":"10.1016\/j.bneo.2026.100253_bib34","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1016\/j.cell.2025.10.010","article-title":"Disparate leukemia mutations converge on nuclear phase-separated condensates","volume":"188","author":"Datar","year":"2025","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bneo.2026.100253_bib35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bneo.2026.100253_bib36","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3390\/cancers17132095","article-title":"NPM1-mutated AML: deciphering the molecular and clinical puzzle in the era of novel treatment strategies","volume":"17","author":"Diamantidis","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bneo.2026.100253_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2016.361","article-title":"NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group","volume":"31","author":"Bisio","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bneo.2026.100253_bib38","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100253_bib39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100253_bib40","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bneo.2026.100253_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.bneo.2026.100253_bib42","doi-asserted-by":"crossref","first-page":"31742","DOI":"10.1074\/jbc.M111.258186","article-title":"Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein","volume":"286","author":"Murai","year":"2011","journal-title":"J Biol Chem"},{"issue":"7386","key":"10.1016\/j.bneo.2026.100253_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10806","article-title":"The same pocket in menin binds both MLL and JUND but has opposite effects on transcription","volume":"482","author":"Huang","year":"2012","journal-title":"Nature"},{"issue":"13 suppl","key":"10.1016\/j.bneo.2026.100253_bib44","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1158\/1538-7445.AM2017-5077","article-title":"Abstract 5077: a novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias","volume":"77","author":"Wu","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.bneo.2026.100253_bib45","series-title":"Monotherapy update from phase 1 portion in phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","author":"Daver","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib46","series-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","author":"Searle","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib47","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib48","article-title":"Revumenib for patients with relapsed or refractory (R\/R) nucleophosmin 1\u2013mutated (NPM1m) acute myeloid leukemia (AML): outcomes by prior treatment in the phase 2 AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","article-title":"A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01757-4","article-title":"A phase 1\/2 study of DS-1594 menin inhibitor in relapsed\/refractory acute leukemias","volume":"18","author":"Senapati","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100253_bib51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.bneo.2026.100253_bib53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib54","article-title":"Monotherapy update from phase 1 portion in phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib56","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib57","article-title":"Revumenib for patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia: outcomes by leukemia type in the phase 2 AUGMENT-101 study","volume":"146","author":"Aldoss","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100253_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156226","article-title":"Combination of icovamenib and GLP-1-based therapeutic agents improves beta cell function and insulin secretion","volume":"168","author":"Balakrishnan","year":"2025","journal-title":"Metabolism - Clinical and Experimental"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41392-023-01627-w","article-title":"Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes","volume":"8","author":"Di Fazio","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7954","key":"10.1016\/j.bneo.2026.100253_bib61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107777","article-title":"Drug-resistant menin variants retain high binding affinity and interactions with MLL1","volume":"300","author":"Ray","year":"2024","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib64","first-page":"258","article-title":"Targeting menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes","volume":"25","author":"Sparbier","year":"2023","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100253_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114901","article-title":"NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML","volume":"43","author":"Heikamp","year":"2024","journal-title":"Cell Rep"},{"issue":"19","key":"10.1016\/j.bneo.2026.100253_bib66","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bneo.2026.100253_bib67","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2026.100253_bib68","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100253_bib69","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib83","article-title":"Preliminary results of a phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"146","author":"Borate","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib86","article-title":"Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors","volume":"146","author":"Tayari","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib87","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bneo.2026.100253_bib70","series-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","author":"Issa","year":"2024"},{"key":"10.1016\/j.bneo.2026.100253_bib71","series-title":"Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML","author":"Jen","year":"2025"},{"issue":"23","key":"10.1016\/j.bneo.2026.100253_bib72","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bneo.2026.100253_bib73","series-title":"Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b ETCTN 10596 study","author":"Mims","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib74","series-title":"Preliminary results of a phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","author":"Borate","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib75","series-title":"Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) acute myeloid leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708","author":"Aldoss","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib76","series-title":"Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML): updated phase 1a\/b results from KOMET-007","author":"Erba","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib77","series-title":"Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007","author":"Roboz","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib78","series-title":"Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: updated phase 1a\/b safety and clinical activity results from KOMET-007","author":"Issa","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib79","series-title":"Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia","author":"Watts","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib80","series-title":"Phase 1b study of bleximenib in combination with venetoclax in acute myeloid leukemia with KMT2A or NPM1 alterations","author":"O\u2019Nions","year":"2025"},{"key":"10.1016\/j.bneo.2026.100253_bib81","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1016\/S2152-2650(25)01665-9","article-title":"AML-418: recommended phase 2 dose (RP2D) determination of bleximenib in combination with venetoclax+azacitidine (VEN+AZA): phase Ib study in newly diagnosed (ND) and relapsed\/refractory (R\/R) acute myeloid leukemia (AML) with KMT2A or NPM1 alterations","volume":"25","author":"Wei","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1016\/j.bneo.2026.100253_bib82","series-title":"Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations","author":"D\u00f6hner","year":"2025"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib88","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.bneo.2026.100253_bib89","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2026.100253_bib90","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100253_bib91","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib92","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to menin inhibitors in MLL leukemia","volume":"15","author":"Gordon","year":"2025","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib93","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/2159-8290.CD-24-1772","article-title":"KAT6A and KAT7 histone acetyltransferase complexes are molecular dependencies and therapeutic targets in NUP98-rearranged acute myeloid leukemia","volume":"15","author":"Michmerhuizen","year":"2025","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bneo.2026.100253_bib94","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/leu.2016.327","article-title":"Complementary activities of DOT1L and menin inhibitors in MLL-rearranged leukemia","volume":"31","author":"Dafflon","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100253_bib95","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-016-0252-7","article-title":"Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia","volume":"9","author":"Feng","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib97","article-title":"TP53 inactivation confers resistance to the menin inhibitor revumenib in acute myeloid leukemia","volume":"146","author":"D'Souza","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100253_bib98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2013-09-525741","article-title":"MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia","volume":"124","author":"Manara","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100253_bib99","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41375-026-02959-6","article-title":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia","volume":"40","author":"Chin","year":"2026","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib100","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib101","article-title":"Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: updated phase 1a\/b safety and clinical activity results from KOMET-007","volume":"146","author":"Issa","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib102","article-title":"Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia","volume":"146","author":"Watts","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib103","article-title":"Phase 1b study of bleximenib in combination with venetoclax in acute myeloid leukemia with KMT2A or NPM1 alterations","volume":"146","author":"O'Nions","year":"2025","journal-title":"Blood"},{"issue":"10388","key":"10.1016\/j.bneo.2026.100253_bib104","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bneo.2026.100253_bib105","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","article-title":"Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Levis","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib106","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41698-025-01013-5","article-title":"Functional cure with single agent olutasidenib in relapsed IDH1\/NPM1 co-mutated AML","volume":"9","author":"Watts","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100253_bib107","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41588-025-02321-z","article-title":"Rapid epigenomic classification of acute leukemia","volume":"57","author":"Steinicke","year":"2025","journal-title":"Nat Genet"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib108","article-title":"Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML","volume":"146","author":"Jen","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib109","article-title":"Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007","volume":"146","author":"Roboz","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib110","article-title":"Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study","volume":"146","author":"Lachowiez","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100253_bib111","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib112","article-title":"A phase 1\/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed\/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias","volume":"146","author":"Chin","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib113","article-title":"Discerning the landscape of menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100253_bib114","series-title":"The novel menin inhibitor ZE63-0302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations","author":"Hertlein","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100253_bib115","article-title":"Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms","volume":"146","author":"Crispino","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100253_bib116","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nm.3830","article-title":"Targeting the MLL complex in castration-resistant prostate cancer","volume":"21","author":"Malik","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100253_bib117","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-17-0580","article-title":"Pharmacologic inhibition of the menin-MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma","volume":"17","author":"Kempinska","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bneo.2026.100253_bib118","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1158\/2159-8290.CD-21-0646","article-title":"MOZ and menin-MLL complexes are complementary regulators of chromatin association and transcriptional output in gastrointestinal stromal tumor","volume":"12","author":"Hemming","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.bneo.2026.100253_bib119","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14348\/molcells.2021.0206","article-title":"Menin enhances androgen receptor-independent proliferation and migration of prostate cancer cells","volume":"45","author":"Kim","year":"2022","journal-title":"Mol Cells"},{"issue":"7","key":"10.1016\/j.bneo.2026.100253_bib120","article-title":"Combined inhibition of KAT6A\/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer","volume":"6","author":"Olsen","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:40Z","timestamp":1790687860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000646"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100253","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menin inhibitors as a treatment for acute leukemia: from bench to the clinic","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100253"}}